Fisher & Paykel Healthcare First Half 2024 Earnings: EPS Beats Expectations

Simply Wall St

December 01, 2023

Fisher & Paykel Healthcare (NZSE:FPH) First Half 2024 Results

Key Financial Results

Revenue: NZ$803.7m (up 16% from 1H 2023).
Net income: NZ$107.3m (up 12% from 1H 2023).
Profit margin: 13% (in line with 1H 2023).
EPS: NZ$0.18 (up from NZ$0.17 in 1H 2023).

earnings-and-revenue-growth — NZSE:FPH Earnings and Revenue Growth December 1st 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Fisher & Paykel Healthcare EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.4%.

Looking ahead, revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 9.8% growth forecast for the Medical Equipment industry in Oceania.

Performance of the market in New Zealand.

The company's shares are up 6.9% from a week ago.

Valuation

It's possible that Fisher & Paykel Healthcare could be overvalued with our 6-factor valuation analysis indicating potential weakness. You can access our in-depth analysis and discover what the outlook is like for the stock by clicking here.

If you're looking to trade Fisher & Paykel Healthcare, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.

With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.

Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.